Authors
Lise J Estcourt, Claudia S Cohn, Monica B Pagano, Claire Iannizzi, Nina Kreuzberger, Nicole Skoetz, Elizabeth S Allen, Evan M Bloch, Gregory Beaudoin, Arturo Casadevall, Dana V Devine, Farid Foroutan, Thomas J Gniadek, Ruchika Goel, Jed Gorlin, Brenda J Grossman, Michael J Joyner, Ryan A Metcalf, Jay S Raval, Todd W Rice, Beth H Shaz, Ralph R Vassallo, Jeffrey L Winters, Aaron AR Tobian
Publication date
2022/9
Journal
Annals of internal medicine
Volume
175
Issue
9
Pages
1310-1321
Publisher
American College of Physicians
Description
Description
Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP.
Methods
These guidelines are based on 2 living systematic reviews of randomized controlled trials (RCTs) evaluating CCP from 1 January 2019 to 26 January 2022. There were 33 RCTs assessing 21 916 participants. The results were summarized using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method. An expert panel reviewed the data using the GRADE framework to formulate recommendations.
Recommendation 1 (Outpatient)
The AABB suggests CCP transfusion …
Total citations
Scholar articles
LJ Estcourt, CS Cohn, MB Pagano, C Iannizzi… - Annals of internal medicine, 2022